NCT07551544 ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed High-Grade Non-Muscle Invasive Papillary Bladder Cancer Status WITHDRAWN Phase PHASE3
NCT07505615 A Phase I-II Study of Novel Oncolytic Virus VG161 Via Intravesical Instillation for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Status COMPLETED Phase PHASE1/PHASE2
NCT07445308 The Study is to Evaluate the Safety and Tolerability of SPGL008 Alone or in Combination With BCG in the Patients With NMIBC, and to Determine the RP2D of SPGL008 Alone or in Combination With BCG.To Evaluate the Preliminary Efficacy of SPGL008 Alone or in Combination With BCG. Status NOT_YET_RECRUITING Phase PHASE1/PHASE2
NCT07424287 A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC Status NOT_YET_RECRUITING Phase PHASE3
NCT07207824 DV+BCG in HER2-Expressing, BCG-Naïve High-Risk NMIBC Status NOT_YET_RECRUITING Phase PHASE3
NCT07064863 A Tumor Immune Biomarker Guided Approach for Improving Response to BCG in Patients With High-risk NMIBC. Status NOT_YET_RECRUITING Phase PHASE1/PHASE2
NCT06991868 A Multicenter Prospective Cohort Study on Monitoring Recurrence of Urothelial Carcinoma Based on Detection of Urinary Microscopic Residual Disease (MRD) Status RECRUITING Phase N/A
NCT06982690 Anesthesia Modality and Oncologic Outcomes in High-Risk NMIBC: A Randomized Trial Status NOT_YET_RECRUITING Phase NA
NCT06889623 Immediate Chemotherapy Following Resection for High-Risk Non-Muscle-Invasive Bladder Cancer Status RECRUITING Phase NA
NCT06810141 ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer Status AVAILABLE Phase N/A
NCT06800963 ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG Status RECRUITING Phase PHASE1/PHASE2
NCT06735287 A Bladder-Sparing Treatment Strategies of Large-Volume Non-Muscle-Invasive Bladder Cancer Status RECRUITING Phase NA
NCT06630871 A Clinical Trial Evaluating the Efficacy and Safety of Disitamab Vedotin Plus Tislelizumab Combined with Re-TURBT in the Treatment of HER-2-high Expression(2+-3+) Non-muscle Invasive Bladder Cancer At High-risk and Very High-risk. Status NOT_YET_RECRUITING Phase PHASE2
NCT06588179 SHR-1501 Combined With SHR-2005 for High-Risk Non-Muscle Invasive Bladder Cancer Which is Not Completely Resectable by TURBt Status NOT_YET_RECRUITING Phase PHASE1/PHASE2
NCT06181266 A Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT05943379 RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects Status RECRUITING Phase PHASE2
NCT05483868 A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer Status RECRUITING Phase PHASE1
NCT05375903 A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) Status COMPLETED Phase PHASE1
NCT05014139 A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC) Status TERMINATED Phase PHASE1
NCT03914794 A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors Status COMPLETED Phase PHASE2